Dr. Anthony J. Smith, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- New York Medical College (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 295
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: New York Medical College
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NY license 172040 -
Critical Care Medicine (Internal Medicine) Physician
NY license 172040
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian/queens Flushing, NY
Medical groups
- New York Queens Medicine and Surgery, P.c. (401 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 295
- Services billed
- 860
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 112 | 75 |
| Established patient office or other outpatient visit, 30-39 minutes | 106 | 81 |
| Test to examine how well the lungs exchange gases | 76 | 76 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 70 | 70 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 62 | 37 |
| Test to determine lung volumes using sensors | 58 | 58 |
| New patient office or other outpatient visit, 45-59 minutes | 33 | 33 |
| Test to determine lung volumes using gas dilution or washout | 18 | 18 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 15 | 15 |
| New patient office or other outpatient visit, 30-44 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in New York, NY | 113 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in New York, NY | 113 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in New York, NY | 57 |
| Prednisone Other prescribers in New York, NY | 48 |
| Azithromycin Other prescribers in New York, NY | 41 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in New York, NY | 40 |
| Fluticasone Propionate Other prescribers in New York, NY | 40 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in New York, NY | 34 |
| Wixela Inhub (fluticasone propion/salmeterol) Other prescribers in New York, NY | 33 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in New York, NY | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $2,425 in total to this clinician.
| Chiesi USA, Inc. | $2,425 |
|---|
| Travel and Lodging | $2,336 |
|---|---|
| Food and Beverage | $88.85 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Chiesi USA, Inc. Jan 24, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $2,336 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $52,998 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Sanofi US Services Inc. · Completed · NCT06208306 - Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi US Services Inc. · Recruiting · NCT07190209 - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04751487
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.